[2] Omenn, G. S., Clin. Chem. Lab. Med. 2004, 42, 1-2.

[3] Schräder, M., Schulz-Knappe, P., Trends Biotechnol. 2001, 19, 55-60.

[4] Schulz-Knappe, P., Zucht, H. D., Heine, G., Jürgens, M. et al., Comb. Chem. High Throughput Screen. 2001, 4, 207-217.

[5] Tammen, H., Mohring, T., Kellmann, M., Pich, A. et al., Clin. Chem. 2004, 50, 545551.

B. L. et al, Proteomics 2005, 5. DO] 10.1002/pmic.200400606

[7] Görg, A., Obermaier, C., Boguth, G., Weiss, W., Electrophoresis 1999, 20, 712717.

[8] Schagger, H., von Jagow, G., Anal. Biochem. 1987, 166, 368-379.

[10] Zhou, H., Bouwman, K., Schotanus, M., Verweij, C. et al., Genome Biol. 2004;5, R28. Epub.

[11] Richter, R., Schulz-Knappe, P., Schrader, M., Standker, L. et al., J. Chromatogr. B Biomed. Sci. Appl. 1999, 726, 25-35.

[12] Tammen H., Schulte, ]., Hess, R., Menzel, C. et al., Proteomics 2005, 5. DO] 10.1002/pmic.200400419

[13] Villanueva, J., Philip, J., Entenberg, D., Chaparro, C. A. et al., Anal. Chem. 2004, 76, 1560-1570.

[14] Petricoin, E. F., Ardekani, A. M., Hitt, B. A., Levine, P. J. et al., Lancet 2002, 359, 572-577.

[16] Diamandis, E. P., Mol. Cell. Proteomics 2004, 3, 367-378.

[17] Tubes and Additives for Venous Blood Specimen Collection; Approved Standard- Fifth Edition, NCCLS, Wayne PA 2003, H1-A5, 23(33).

[18] Haab, B. B., Geierstanger, B. H., Michai-lidis, G., Vitzthum, F. et al., Proteomics 2005, 5. DOI 10.1002/pmic.200400470

[19] Procedures for the Handling and Processing of Blood Specimens; Approved Guideline - Second Edition, NCCLS, Wayne PA 1999, 19(21).

[20] Radha, C., Muralidhara, B. K., Kumar, P. R., Tasneem, R. et al., Indian J. Biochem. Biophys. 1998, 35, 76-85.

[21] Gupta, C. K., Leszczynski, J., Gupta, R. K., Siber, G. R., Vaccine 1996, 14, 1417-1420.

[22] Gekko, K., Morikawa,T., J. Biochem. 1981, 90, 39-50.

[23] Sousa, R., Acta. Crystallogr. D. Biol. Crys-tallogr. 1995, 51, 271-277.

[24] Ruan, K., Xu, C., Li, T., Li, J. et al., Eur. J. Biochem. 2003, 270(8), 1654-1661.

[25] Liao, Y. H., Brown, M. B., Quader, A., Martin, G. P., Pharm. Res. 2002, 19, 18541861.

[26] Schuchard, M. D., Mehigh, R. J., Cockrill, S., Lipscomb, G. T. et al., Biotechniques 2005, in press.

[28] Sweeney, B., Proudfoot, K., Parton, A. H., King, L. M. et al., Anal. Biochem. 1997, 245, 107-109.

[29] Marshall, J., Kupchak, P., Zhu W., Yantha, J. et al., J. Proteome Res. 2003, 2, 361-372.

[30] Steinmetz, J., Tarallo, P., Fournier, B., Caces, E. et al., Eur. J. Clin. Chem. Clin. Biochem. 1995, 33, 337-342.

[31], International Standards Organization (ISO) ISO/DIS 5725-1, Geneva: ISO, 1990.

[32] Büttner, J., Eur. J. Clin. Chem. Clin. Biochem. 1995, 33, 981-988.

[33] Favaloro, E. J., Soltani, S., McDonald, J. et al., Am. J. Clin. Pathol. 2004, 122, 686692.

[34] Granger, C. B., Van Eyk, J. E., Mockrin, S. C., Anderson, N. L., Circulation 2004, 109, 1697-1703.

[35] Baudner, S., Haupt, H., Hubner, R., J. Clin. Lab. Anal. 1994, 8, 177-190.

[36] Whicher, J. T., Clin Biochem 1998, 31, 459-465.

[37] Johnson, A. M., Whicher, J. T., Clin. Chem. Lab. Med. 2001, 39(11), 1123-1138.

[38] Petersen, P. H., Henny, J., Clin. Chem. Lab. Med. (special issue) Reference Values 2004, 42, 7.

Immunoassay and antibody microarray analysis of the HUPO Plasma Proteome Project reference specimens: Systematic variation between sample types and calibration of mass spectrometry data*

Brian B. Haab, Bernhard H. Geierstanger, George Michailidis, Frank Vitzthum,

Sara Forrester, Ryan Okon, Petri Saviranta, Achim Brinker, Martin Sorette, Lorah Perlee,

Shubha Suresh, Garry Drwal, Joshua N. Adkins and Gilbert S. Omenn

Four different immunoassay and antibody microarray methods performed at four different sites were used to measure the levels of a broad range of proteins (N = 323 assays; 39, 88, 168, and 28 assays at the respective sites; 237 unique ana-lytes) in the human serum and plasma reference specimens distributed by the Plasma Proteome Project (PPP) of the HUPO. The methods provided a means to (1) assess the level of systematic variation in protein abundances associated with blood preparation methods (serum, citrate-anticoagulated-plasma, EDTA-antic-oagulated-plasma, or heparin-anticoagulated-plasma) and (2) evaluate the dependence on concentration of MS-based protein identifications from data sets using the HUPO specimens. Some proteins, particularly cytokines, had highly variable concentrations between the different sample preparations, suggesting specific effects of certain anticoagulants on the stability or availability ofthese proteins. The linkage of antibody-based measurements from 66 different analytes with the combined MS/MS data from 18 different laboratories showed that protein detection and the quality of MS data increased with analyte concentration. The conclusions from these initial analyses are that the optimal blood preparation method is variable between analytes and that the discovery of blood proteins by MS can be extended to concentrations below the ng/mL range under certain circumstances. Continued developments in antibody-based methods will further advance the scientific goals of the PPP.

* Originally published in Proteomics 2005, 13, 3278-3291

92 4 Immunoassay and antibody microarray analysis of the HUPO Plasma Proteome Project 4.1

Was this article helpful?

0 0

Post a comment